Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study
Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event. Objectives: To identify patient characteristics associated with VTE recurrence...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003376 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555698728566784 |
|---|---|
| author | Isabelle Mahé Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Lucas Andre Sylvain Van Roy Ruth Mokgokong Laurent Bertoletti |
| author_facet | Isabelle Mahé Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Lucas Andre Sylvain Van Roy Ruth Mokgokong Laurent Bertoletti |
| author_sort | Isabelle Mahé |
| collection | DOAJ |
| description | Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event. Objectives: To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients. Methods: An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge. The main outcomes were VTE recurrence and bleeding. For both outcomes, the proportions of patients who experienced the outcome were calculated for different patient characteristics. AC switching following VTE recurrence and bleeding was tracked using Anatomical Therapeutic Chemical codes. Results: A total of 31,771 patients received LMWH, of whom 1925 (6.1%) experienced VTE recurrence and 1804 (5.7%) bleeding. Most recurrent VTE and bleeding events occurred within 6 months after the initial VTE event. The proportion of patients with VTE recurrence and bleeding varied between cancer types. Most patients who experienced VTE recurrence or bleeding continued to receive LMWH. Eleven percent of patients with VTE recurrence experienced a further recurrent VTE event within 3 months. Conclusion: More than 10% of patients who received LMWH for cancer-associated VTE experienced VTE recurrence or bleeding. AC management options in this patient population should be prospectively assessed in clinical trials. |
| format | Article |
| id | doaj-art-b0347de83d97423096668ee4fc3f0877 |
| institution | Kabale University |
| issn | 2475-0379 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj-art-b0347de83d97423096668ee4fc3f08772025-01-08T04:53:16ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792025-01-0191102642Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort studyIsabelle Mahé0Gaelle Gusto1Nadia Quignot2Artak Khachatryan3Jose Chaves4Audrey Moniot5Lucas Andre6Sylvain Van Roy7Ruth Mokgokong8Laurent Bertoletti9Université Paris Cité, Paris, France; Assistance Publique des Hôpitaux de Paris, Hôpital Louis Mourier, Service de Médecine Interne, Inserm Unité Mixte de Recherche_S1140, Innovations Thérapeutiques en Hémostase, Paris, France; Correspondence Isabelle Mahé, Université Paris Cité, Assistance Publique des Hôpitaux de Paris, Hôpital Louis Mourier, Colombes 92700, France.Certara France, Paris, FranceCertara France, Paris, FranceCertara UK, London, United KingdomPfizer SLU, Madrid, SpainPfizer SAS, Paris, FrancePfizer SAS, Paris, FrancePfizer SAS, Paris, FrancePfizer Ltd, Tadworth, United KingdomService de Médecine Vasculaire et Thérapeutique, Centre Hospitalo Universitaire de St-Etienne, Saint-Etienne, France; Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, France; Institut national de la santé et de la recherche médicale, Centre d'Investigation Clinique-1408, Centre Hospitalo Universitaire de Saint-Etienne, Saint-Etienne, FranceBackground: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event. Objectives: To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients. Methods: An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge. The main outcomes were VTE recurrence and bleeding. For both outcomes, the proportions of patients who experienced the outcome were calculated for different patient characteristics. AC switching following VTE recurrence and bleeding was tracked using Anatomical Therapeutic Chemical codes. Results: A total of 31,771 patients received LMWH, of whom 1925 (6.1%) experienced VTE recurrence and 1804 (5.7%) bleeding. Most recurrent VTE and bleeding events occurred within 6 months after the initial VTE event. The proportion of patients with VTE recurrence and bleeding varied between cancer types. Most patients who experienced VTE recurrence or bleeding continued to receive LMWH. Eleven percent of patients with VTE recurrence experienced a further recurrent VTE event within 3 months. Conclusion: More than 10% of patients who received LMWH for cancer-associated VTE experienced VTE recurrence or bleeding. AC management options in this patient population should be prospectively assessed in clinical trials.http://www.sciencedirect.com/science/article/pii/S2475037924003376cohort studieshemorrhageheparinlow-molecular-weightneoplasmsrecurrence |
| spellingShingle | Isabelle Mahé Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Lucas Andre Sylvain Van Roy Ruth Mokgokong Laurent Bertoletti Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study Research and Practice in Thrombosis and Haemostasis cohort studies hemorrhage heparin low-molecular-weight neoplasms recurrence |
| title | Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study |
| title_full | Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study |
| title_fullStr | Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study |
| title_full_unstemmed | Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study |
| title_short | Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study |
| title_sort | occurrence and management of thrombosis recurrence and bleeding in low molecular weight heparin treated patients with cancer associated thrombosis a french nationwide cohort study |
| topic | cohort studies hemorrhage heparin low-molecular-weight neoplasms recurrence |
| url | http://www.sciencedirect.com/science/article/pii/S2475037924003376 |
| work_keys_str_mv | AT isabellemahe occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT gaellegusto occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT nadiaquignot occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT artakkhachatryan occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT josechaves occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT audreymoniot occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT lucasandre occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT sylvainvanroy occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT ruthmokgokong occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy AT laurentbertoletti occurrenceandmanagementofthrombosisrecurrenceandbleedinginlowmolecularweightheparintreatedpatientswithcancerassociatedthrombosisafrenchnationwidecohortstudy |